kappa-Opioid receptor signaling and brain reward function

Brain Research Reviews

Volumn 62, Issue 1, 2009, Pages 127-146

  Bruijnzeel, Adrie W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Brain reward function; Drug addiction; Dynorphins; Negative mood state; Neuropeptides

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; ALCOHOL; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; COCAINE; DIAMORPHINE; DOPAMINE; DYNORPHIN A; DYNORPHIN A [1-8][1 (N METHYLTYROSINE) 7 (N METHYLARGININE) 8 DEXTRO LEUCINE N ETHYLAMIDE]; DYNORPHIN B; ENADOLINE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; MORPHINE; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALFURAFINE; NALOXONE BENZOYLHYDRAZONE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; NORBINALTORPHIMINE; PHOSPHOPROTEIN DARPP 32; PRODYNORPHIN; SALVINORIN A; SEROTONIN UPTAKE INHIBITOR;

ALCOHOLISM; BRAIN FUNCTION; CAUDATE NUCLEUS; COCAINE DEPENDENCE; CORPUS STRIATUM; DEPRESSION; DOPAMINE RELEASE; DOSE RESPONSE; DRUG ABUSE; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; HEROIN DEPENDENCE; HUMAN; LOW DRUG DOSE; MORPHINE ADDICTION; NEUROTOXICITY; NONHUMAN; NORADRENALIN RELEASE; OPIATE ADDICTION; PRIORITY JOURNAL; PUTAMEN; REINFORCEMENT; REVIEW; REWARD; SIGNAL TRANSDUCTION; TOBACCO DEPENDENCE; TRANQUILIZING ACTIVITY;

ANIMALS; BRAIN; DYNORPHINS; HUMANS; RECEPTORS, OPIOID, KAPPA; REWARD; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 70449658803     PISSN: 01650173     EISSN: 18726321     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2009.09.008     Document Type: Review

References (266)

1. Agmo A., Paredes R.G., and Contreras J.L. Opioids and sexual behavior in the male rabbit: the role of central and peripheral opioid receptors. J. Neural. Transm. Gen. Sect. 97 (1994) 211-223
2. Amalric M., Cline E.J., Martinez Jr. J.L., Bloom F.E., and Koob G.F. Rewarding properties of beta-endorphin as measured by conditioned place preference. Psychopharmacology (Berl.) 91 (1987) 14-19
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (2000), American Psychiatric Press, Washington, DC
4. Antelman S.M., and Caggiula A.R. Norepinephrine-dopamine interactions and behavior. Science 195 (1977) 646-653
5. Antelman S.M., and Szechtman H. Tail pinch induces eating in sated rats which appears to depend on nigrostriatal dopamine. Science 189 (1975) 731-733
6. Apicella P., Ljungberg T., Scarnati E., and Schultz W. Responses to reward in monkey dorsal and ventral striatum. Exp. Brain Res. 85 (1991) 491-500
7. Aron A., Fisher H., Mashek D.J., Strong G., Li H., and Brown L.L. Reward, motivation, and emotion systems associated with early-stage intense romantic love. J. Neurophysiol. 94 (2005) 327-337
8. Attali B., Gouarderes C., Mazarguil H., Audigier Y., and Cros J. Differential interaction of opiates to multiple "kappa" binding sites in the guinea-pig lumbo-sacral spinal cord. Life Sci. 31 (1982) 1371-1375
9. Attali B., Saya D., and Vogel Z. Kappa-opiate agonists inhibit adenylate cyclase and produce heterologous desensitization in rat spinal cord. J. Neurochem. 52 (1989) 360-369
10. Badiani A., Rajabi H., Nencini P., and Stewart J. Modulation of food intake by the kappa opioid U-50,488H: evidence for an effect on satiation. Behav. Brain Res. 118 (2001) 179-186
11. Bals-Kubik R., Ableitner A., Herz A., and Shippenberg T.S. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J. Pharmacol. Exp. Ther. 264 (1993) 489-495
12. Barr A.M., Fiorino D.F., and Phillips A.G. Effects of withdrawal from an escalating dose schedule of d-amphetamine on sexual behavior in the male rat. Pharmacol. Biochem. Behav. 64 (1999) 597-604
13. Beadles-Bohling A.S., and Wiren K.M. Anticonvulsive effects of kappa-opioid receptor modulation in an animal model of ethanol withdrawal. Genes Brain Behav. 5 (2006) 483-496
14. Beardsley P.M., Howard J.L., Shelton K.L., and Carroll F.I. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl.) 183 (2005) 118-126
15. Beczkowska I.W., Bowen W.D., and Bodnar R.J. Central opioid receptor subtype antagonists differentially alter sucrose and deprivation-induced water intake in rats. Brain Res. 589 (1992) 291-301
16. Biala G., and Weglinska B. Blockade of the expression of mecamylamine-precipitated nicotine withdrawal by calcium channel antagonists. Pharmacol. Res. 51 (2005) 483-488
17. Bolanos C.A., Garmsen G.M., Clair M.A., and McDougall S.A. Effects of the kappa-opioid receptor agonist U-50,488 on morphine-induced place preference conditioning in the developing rat. Eur. J. Pharmacol. 317 (1996) 1-8
18. Bolger N., DeLongis A., Kessler R.C., and Schilling E.A. Effects of daily stress on negative mood. J. Pers. Soc. Psychol. 57 (1989) 808-818
19. Borgkvist A., and Fisone G. Psychoactive drugs and regulation of the cAMP/PKA/DARPP-32 cascade in striatal medium spiny neurons. Neurosci. Biobehav. Rev. 31 (2007) 79-88
20. Braida D., Limonta V., Capurro V., Fadda P., Rubino T., Mascia P., Zani A., Gori E., Fratta W., Parolaro D., and Sala M. Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward. Biol. Psychiatry 63 (2008) 286-292
21. Brand A.N., Jolles J., and Gispen-de W.C. Recall and recognition memory deficits in depression. J. Affect. Disord. 25 (1992) 77-86
22. Britt J.P., and McGehee D.S. Presynaptic opioid and nicotinic receptor modulation of dopamine overflow in the nucleus accumbens. J. Neurosci. 28 (2008) 1672-1681
23. Britton D.R., Koob G.F., Rivier J., and Vale W. Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Sci. 31 (1982) 363-367
24. Bruijnzeel A.W., and Gold M.S. The role of corticotropin-releasing factor-like peptides in cannabis, nicotine, and alcohol dependence. Brain Res. Brain Res. Rev. 49 (2005) 505-528
25. Bruijnzeel A.W., Lewis B., Bajpai L.K., Morey T.E., Dennis D.M., and Gold M. Severe deficit in brain reward function associated with fentanyl withdrawal in rats. Biol. Psychiatry 59 (2006) 477-480
26. Bruijnzeel A.W., Zislis G., Wilson C., and Gold M.S. Antagonism of CRF receptors prevents the deficit in brain reward function associated with precipitated nicotine withdrawal in rats. Neuropsychopharmacology 32 (2007) 955-963
27. Cadoni C., and Di C.G. Reciprocal changes in dopamine responsiveness in the nucleus accumbens shell and core and in the dorsal caudate-putamen in rats sensitized to morphine. Neuroscience 90 (1999) 447-455
28. Cador M., Ahmed S.H., Koob G.F., Le M.M., and Stinus L. Corticotropin-releasing factor induces a place aversion independent of its neuroendocrine role. Brain Res. 597 (1992) 304-309
29. Carlezon Jr. W.A., Beguin C., Dinieri J.A., Baumann M.H., Richards M.R., Todtenkopf M.S., Rothman R.B., Ma Z., Lee D.Y., and Cohen B.M. Depressive-like effects of the κ-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J. Pharmacol. Exp. Ther. 316 (2006) 440-447
30. Chen J.C., Smith E.R., Cahill M., Cohen R., and Fishman J.B. The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci. 52 (1993) 389-396
31. Chesselet M.F., Cheramy A., Reisine T.D., and Glowinski J. Morphine and delta-opiate agonists locally stimulate in vivo dopamine release in cat caudate nucleus. Nature 291 (1981) 320-322
32. Chieng B., and Williams J.T. Increased opioid inhibition of GABA release in nucleus accumbens during morphine withdrawal. J. Neurosci. 18 (1998) 7033-7039
33. Church W.H., Justice Jr. J.B., and Byrd L.D. Extracellular dopamine in rat striatum following uptake inhibition by cocaine, nomifensine and benztropine. Eur. J. Pharmacol. 139 (1987) 345-348
34. Civelli O., Douglass J., Goldstein A., and Herbert E. Sequence and expression of the rat prodynorphin gene. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 4291-4295
35. Clark J.A., Liu L., Price M., Hersh B., Edelson M., and Pasternak G.W. Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype. J. Pharmacol. Exp. Ther. 251 (1989) 461-468
36. Comb M., Seeburg P.H., Adelman J., Eiden L., and Herbert E. Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA. Nature 295 (1982) 663-666
37. Connor M., and Kitchen I. Has the sun set on kappa3-opioid receptors?. Br. J. Pharmacol. 147 (2006) 349-350
38. Cooper S.J., Jackson A., Morgan R., and Carter R. Evidence for opiate receptor involvement in the consumption of a high palatability diet in nondeprived rats. Neuropeptides 5 (1985) 345-348
39. Cryan J.F., Hoyer D., and Markou A. Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol. Psychiatry 54 (2003) 49-58
40. Cryan J.F., Markou A., and Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 23 (2002) 238-245
41. D'Addario C., Di B.M., Candeletti S., and Romualdi P. The kappa-opioid receptor agonist U-69593 prevents cocaine-induced phosphorylation of DARPP-32 at Thr(34) in the rat brain. Brain Res. Bull. 73 (2007) 34-39
42. Daunais J.B., Roberts D.C., and McGinty J.F. Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum. Neuroreport 4 (1993) 543-546
43. Daunais J.B., Roberts D.C., and McGinty J.F. Short-term cocaine self administration alters striatal gene expression. Brain Res. Bull. 37 (1995) 523-527
44. de Wied D. Melanotropins as neuropeptides. Ann. N. Y. Acad. Sci. 680 (1993) 20-28
45. Delfs J.M., Zhu Y., Druhan J.P., and Aston-Jones G. Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature 403 (2000) 430-434
46. Deviche P., and Moore F.L. Opioid kappa-receptor agonists suppress sexual behaviors in male rough-skinned newts (Taricha granulosa). Horm. Behav. 21 (1987) 371-383
47. Di Benedetto M., D'Addario C., Collins S., Izenwasser S., Candeletti S., and Romualdi P. Role of serotonin on cocaine-mediated effects on prodynorphin gene expression in the rat brain. J. Mol. Neurosci. 22 (2004) 213-222
48. Di Chiara G., and Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 5274-5278
49. Di Chiara G., and Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 244 (1988) 1067-1080
50. Done C., Silverstone P., and Sharp T. Effect of naloxone-precipitated morphine withdrawal on noradrenaline release in rat hippocampus in vivo. Eur. J. Pharmacol. 215 (1992) 333-336
51. Donzanti B.A., Althaus J.S., Payson M.M., and Von Voigtlander P.F. Kappa agonist-induced reduction in dopamine release: site of action and tolerance. Res. Commun. Chem. Pathol. Pharmacol. 78 (1992) 193-210
52. Dorsa D.M., van Ree J.M., and de W.D. Effects of [Des-Tyr 1]-gamma-endorphin and alpha-endorphin on substantia nigra self-stimulation. Pharmacol. Biochem. Behav. 10 (1979) 899-905
53. El Daly E., Chefer V., Sandill S., and Shippenberg T.S. Modulation of the neurotoxic effects of methamphetamine by the selective kappa-opioid receptor agonist U69593. J. Neurochem. 74 (2000) 1553-1562
54. Evans R.M., and Zamponi G.W. Presynaptic Ca2+channels-integration centers for neuronal signaling pathways. Trends Neurosci. 29 (2006) 617-624
55. Fagergren P., Smith H.R., Daunais J.B., Nader M.A., Porrino L.J., and Hurd Y.L. Temporal upregulation of prodynorphin mRNA in the primate striatum after cocaine self-administration. Eur. J. Neurosci. 17 (2003) 2212-2218
56. Fallon J.H. Collateralization of monoamine neurons: mesotelencephalic dopamine projections to caudate, septum, and frontal cortex. J. Neurosci. 1 (1981) 1361-1368
57. Fan W., Boston B.A., Kesterson R.A., Hruby V.J., and Cone R.D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 385 (1997) 165-168
58. Fienberg A.A., and Greengard P. The DARPP-32 knockout mouse. Brain Res. Brain Res. Rev 31 (2000) 313-319
59. Finnerty E.P., and Chan S.H. Morphine suppression of substantia nigra zona reticulata neurons in the rat: implicated role for a novel striatonigral feedback mechanism. Eur. J. Pharmacol. 59 (1979) 307-310
60. Fiorino D.F., and Phillips A.G. Facilitation of sexual behavior and enhanced dopamine efflux in the nucleus accumbens of male rats after d-amphetamine-induced behavioral sensitization. J. Neurosci. 19 (1999) 456-463
61. Fischli W., Goldstein A., Hunkapiller M.W., and Hood L.E. Isolation and amino acid sequence analysis of a 4,000-dalton dynorphin from porcine pituitary. Proc. Natl. Acad. Sci. U. S. A. 79 (1982) 5435-5437
62. Floresco S.B., Todd C.L., and Grace A.A. Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. J. Neurosci. 21 (2001) 4915-4922
63. Fouriezos G., Hansson P., and Wise R.A. Neuroleptic-induced attenuation of brain stimulation reward in rats. J. Comp. Physiol. Psychol. 92 (1978) 661-671
64. Frankel P.S., Alburges M.E., Bush L., Hanson G.R., and Kish S.J. Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users. Neuropharmacology 55 (2008) 41-46
65. Funada M., Suzuki T., Narita M., Misawa M., and Nagase H. Blockade of morphine reward through the activation of kappa-opioid receptors in mice. Neuropharmacology 32 (1993) 1315-1323
66. Gerfen C.R. Basal Ganglia. In: Paxinos G. (Ed). The Rat Nervous System (2004), Elsevier Academic Press, San Diego, CA 455-509
67. Glick S.D., Maisonneuve I.M., Raucci J., and Archer S. Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res. 681 (1995) 147-152
68. Gold M.S., Redmond Jr. D.E., and Kleber H.D. Clonidine blocks acute opiate-withdrawal symptoms. Lancet 2 (1978) 599-602
69. Goldstein A., Fischli W., Lowney L.I., Hunkapiller M., and Hood L. Porcine pituitary dynorphin: complete amino acid sequence of the biologically active heptadecapeptide. Proc. Natl. Acad. Sci. U. S. A. 78 (1981) 7219-7223
70. Goldstein A., and Ghazarossian V.E. Immunoreactive dynorphin in pituitary and brain. Proc. Natl. Acad. Sci. U. S. A. 77 (1980) 6207-6210
71. Goldstein A., Tachibana S., Lowney L.I., Hunkapiller M., and Hood L. Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc. Natl. Acad. Sci. U. S. A. 76 (1979) 6666-6670
72. Gomez R.G., Fleming S.H., Keller J., Flores B., Kenna H., DeBattista C., Solvason B., and Schatzberg A.F. The neuropsychological profile of psychotic major depression and its relation to cortisol. Biol. Psychiatry 60 (2006) 472-478
73. Gong W., Neill D., and Justice Jr. J.B. Conditioned place preference and locomotor activation produced by injection of psychostimulants into ventral pallidum. Brain Res. 707 (1996) 64-74
74. Gong W., Neill D., and Justice Jr. J.B. 6-Hydroxydopamine lesion of ventral pallidum blocks acquisition of place preference conditioning to cocaine. Brain Res. 754 (1997) 103-112
75. Gosnell B.A. Involvement of mu opioid receptors in the amygdala in the control of feeding. Neuropharmacology 27 (1988) 319-326
76. Gray A.M., Rawls S.M., Shippenberg T.S., and McGinty J.F. The kappa-opioid agonist, U-69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum. J. Neurochem. 73 (1999) 1066-1074
77. Groenewegen H.J., Vermeulen-Van der Z.E., te K.A., and Witter M.P. Organization of the projections from the subiculum to the ventral striatum in the rat. A study using anterograde transport of Phaseolus vulgaris leucoagglutinin. Neuroscience 23 (1987) 103-120
78. Gucciardi E., Celasun N., Ahmad F., and Stewart D.E. Eating disorders. BMC Womens Health 4 Suppl 1 (2004) S21
79. Gulya K., Orpana A.K., Sikela J.M., and Hoffman P.L. Prodynorphin and vasopressin mRNA levels are differentially affected by chronic ethanol ingestion in the mouse. Brain Res. Mol. Brain Res. 20 (1993) 1-8
80. Hahn B., Stolerman I.P., and Shoaib M. Kappa-opioid receptor modulation of nicotine-induced behaviour. Neuropharmacology 39 (2000) 2848-2855
81. Hamilton M.E., and Bozarth M.A. Feeding elicited by dynorphin (1-13) microinjections into the ventral tegmental area in rats. Life Sci. 43 (1988) 941-946
82. Hanson G.R., Merchant K.M., Letter A.A., Bush L., and Gibb J.W. Methamphetamine-induced changes in the striatal-nigral dynorphin system: role of D-1 and D-2 receptors. Eur. J. Pharmacol. 144 (1987) 245-246
83. Hanson G.R., Merchant K.M., Letter A.A., Bush L., and Gibb J.W. Characterization of methamphetamine effects on the striatal-nigral dynorphin system. Eur. J. Pharmacol. 155 (1988) 11-18
84. Harris R.B., Zhou J., Youngblood B.D., Rybkin I.I., Smagin G.N., and Ryan D.H. Effect of repeated stress on body weight and body composition of rats fed low- and high-fat diets. Am. J. Physiol. 275 (1998) R1928-R1938
85. Heidbreder C.A., Babovic-Vuksanovic D., Shoaib M., and Shippenberg T.S. Development of behavioral sensitization to cocaine: influence of kappa opioid receptor agonists. J. Pharmacol. Exp. Ther. 275 (1995) 150-163
86. Heidbreder C.A., Goldberg S.R., and Shippenberg T.S. The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat. Brain Res. 616 (1993) 335-338
87. Heijna M.H., Padt M., Hogenboom F., Portoghese P.S., Mulder A.H., and Schoffelmeer A.N. Opioid receptor-mediated inhibition of dopamine and acetylcholine release from slices of rat nucleus accumbens, olfactory tubercle and frontal cortex. Eur. J. Pharmacol. 181 (1990) 267-278
88. Heimer L., and Wilson R.D. The subcortical projections of the allocortex: similarities in the neural associations of the hippocampus, the piriform cortex, and the neocortex. Golgi centenial symposium proceedings (1975), Raven, New York 177-193
89. Hemmings Jr. H.C., Greengard P., Tung H.Y., and Cohen P. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 310 (1984) 503-505
90. Hemmings Jr. H.C., Williams K.R., Konigsberg W.H., and Greengard P. DARPP-32, a dopamine-and adenosine 3′:5′-monophosphate-regulated neuronal phosphoprotein. I. Amino acid sequence around the phosphorylated threonine. J. Biol. Chem. 259 (1984) 14486-14490
91. Henry D.J., Grandy D.K., Lester H.A., Davidson N., and Chavkin C. Kappa-opioid receptors couple to inwardly rectifying potassium channels when coexpressed by Xenopus oocytes. Mol. Pharmacol. 47 (1995) 551-557
92. Hernandez L., and Hoebel B.G. Feeding and hypothalamic stimulation increase dopamine turnover in the accumbens. Physiol. Behav. 44 (1988) 599-606
93. Hirning L.D., Fox A.P., McCleskey E.W., Olivera B.M., Thayer S.A., Miller R.J., and Tsien R.W. Dominant role of N-type Ca2+ channels in evoked release of norepinephrine from sympathetic neurons. Science 239 (1988) 57-61
94. Hjelmstad G.O., and Fields H.L. Kappa opioid receptor inhibition of glutamatergic transmission in the nucleus accumbens shell. J. Neurophysiol. 85 (2001) 1153-1158
95. Hjelmstad G.O., and Fields H.L. Kappa opioid receptor activation in the nucleus accumbens inhibits glutamate and GABA release through different mechanisms. J. Neurophysiol. 89 (2003) 2389-2395
96. Horikawa S., Takai T., Toyosato M., Takahashi H., Noda M., Kakidani H., Kubo T., Hirose T., Inayama S., and Hayashida H. Isolation and structural organization of the human preproenkephalin B gene. Nature 306 (1983) 611-614
97. Hughes J., Smith T.W., Kosterlitz H.W., Fothergill L.A., Morgan B.A., and Morris H.R. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 258 (1975) 577-580
98. Hurd Y.L., Brown E.E., Finlay J.M., Fibiger H.C., and Gerfen C.R. Cocaine self-administration differentially alters mRNA expression of striatal peptides. Brain Res. Mol. Brain Res. 13 (1992) 165-170
99. Hurd Y.L., and Herkenham M. Molecular alterations in the neostriatum of human cocaine addicts. Synapse 13 (1993) 357-369
100. Hurd Y.L., Herman M.M., Hyde T.M., Bigelow L.B., Weinberger D.R., and Kleinman J.E. Prodynorphin mRNA expression is increased in the patch vs matrix compartment of the caudate nucleus in suicide subjects. Mol. Psychiatry 2 (1997) 495-500
101. Ignatov I., Kovalenko V.S., Andreev B.V., and Titov M.I. Effect of leu- and met-enkephalins on the brain's reinforcement systems. Bull. Eksp. Biol. Med. 92 (1981) 33-35
102. Ise Y., Narita M., Nagase H., and Suzuki T. Modulation of kappa-opioidergic systems on mecamylamine-precipitated nicotine-withdrawal aversion in rats. Neurosci. Lett. 323 (2002) 164-166
103. Isola R., Zhang H., Tejwani G.A., Neff N.H., and Hadjiconstantinou M. Acute nicotine changes dynorphin and prodynorphin mRNA in the striatum. Psychopharmacology (Berl.) 201 (2009) 507-516
104. Iwamoto E.T. Place-conditioning properties of mu, kappa, and sigma opioid agonists. Alcohol Drug Res. 6 (1985) 327-339
105. Iwatsubo K., and Clouet D.H. Effects of morphine and haloperidol on the electrical activity of rat nigrostriatal neurons. J. Pharmacol. Exp. Ther. 202 (1977) 429-436
106. Jellinger K.A. Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. J. Neural. Transm. Suppl. (2007) 91-104
107. Jordan B.A., and Devi L.A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399 (1999) 697-700
108. Kakidani H., Furutani Y., Takahashi H., Noda M., Morimoto Y., Hirose T., Asai M., Inayama S., Nakanishi S., and Numa S. Cloning and sequence analysis of cDNA for porcine beta-neo-endorphin/dynorphin precursor. Nature 298 (1982) 245-249
109. Kangawa K., and Matsuo H. alpha-Neo-endorphin : a "big" Leu-enkephalin with potent opiate activity from porcine hypothalami. Biochem. Biophys. Res. Commun. 86 (1979) 153-160
110. Kangawa K., Minamino N., Chino N., Sakakibara S., and Matsuo H. The complete amino acid sequence of alpha-neo-endorphin. Biochem. Biophys. Res. Commun. 99 (1981) 871-878
111. Kanner A.M. Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol. Psychiatry 54 (2003) 388-398
112. Kennedy S.H., Dickens S.E., Eisfeld B.S., and Bagby R.M. Sexual dysfunction before antidepressant therapy in major depression. J. Affect. Disord. 56 (1999) 201-208
113. Khachaturian H., Watson S.J., Lewis M.E., Coy D., Goldstein A., and Akil H. Dynorphin immunocytochemistry in the rat central nervous system. Peptides 3 (1982) 941-954
114. Kinouchi K., Maeda S., Saito K., Inoki R., Fukumitsu K., and Yoshiya I. Effects of pentazocine and other opioids on the potassium-evoked release of [3H]noradrenaline from guinea pig cortical slices. Eur. J. Pharmacol. 164 (1989) 63-68
115. Klitenick M.A., Deutch A.Y., Churchill L., and Kalivas P.W. Topography and functional role of dopaminergic projections from the ventral mesencephalic tegmentum to the ventral pallidum. Neuroscience 50 (1992) 371-386
116. Knoll A.T., Meloni E.G., Thomas J.B., Carroll F.I., and Carlezon Jr. W.A. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J. Pharmacol. Exp. Ther. 323 (2007) 838-845
117. Koepp M.J., Gunn R.N., Lawrence A.D., Cunningham V.J., Dagher A., Jones T., Brooks D.J., Bench C.J., and Grasby P.M. Evidence for striatal dopamine release during a video game. Nature 393 (1998) 266-268
118. Konkoy C.S., and Childers S.R. Dynorphin-selective inhibition of adenylyl cyclase in guinea pig cerebellum membranes. Mol. Pharmacol. 36 (1989) 627-633
119. Koob G.F. A role for brain stress systems in addiction. Neuron 59 (2008) 11-34
120. Koob G.F. Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology 56 Suppl. 1 (2009) 18-31
121. Koob G.F., and Le Moal M. Plasticity of reward neurocircuitry and the "dark side" of drug addiction. Nat. Neurosci. 8 (2005) 1442-1444
122. Koob G.F., Sanna P.P., and Bloom F.E. Neuroscience of addiction. Neuron 21 (1998) 467-476
123. Krasnova I.N., and Cadet J.L. Methamphetamine toxicity and messengers of death. Brain Res. Rev. 60 (2009) 379-407
124. Kuzmin A.V., Semenova S., Gerrits M.A., Zvartau E.E., and van Ree J.M. Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice. Eur. J. Pharmacol. 321 (1997) 265-271
125. Land B.B., Bruchas M.R., Lemos J.C., Xu M., Melief E.J., and Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J. Neurosci. 28 (2008) 407-414
126. Lemke M.R. Depressive symptoms in Parkinson's disease. Eur. J. Neurol. 15 Suppl. 1 (2008) 21-25
127. Leshner A.I., Remler H., Biegon A., and Samuel D. Desmethylimipramine (DMI) counteracts learned helplessness in rats. Psychopharmacology (Berl.) 66 (1979) 207-208
128. Levine A.S., Grace M., Billington C.J., and Portoghese P.S. Nor-binaltorphimine decreases deprivation and opioid-induced feeding. Brain Res. 534 (1990) 60-64
129. Levine A.S., Rogers B., Kneip J., Grace M., and Morley J.E. Effect of centrally administered corticotropin releasing factor (CRF) on multiple feeding paradigms. Neuropharmacology 22 (1983) 337-339
130. Levine S. Developmental determinants of sensitivity and resistance to stress. Psychoneuroendocrinology 30 (2005) 939-946
131. Lewin B., Cassimeris L., Lingappa V.R., and Plopper G. Cells (2007), Jones and Bartlett Publishers, Sudbury, MA
132. Lewitt P.A. Levodopa for the treatment of Parkinson's disease. N. Engl. J. Med. 359 (2008) 2468-2476
133. Leyton M., and Stewart J. The stimulation of central kappa opioid receptors decreases male sexual behavior and locomotor activity. Brain Res. 594 (1992) 56-74
134. Lindholm S., Ploj K., Franck J., and Nylander I. Repeated ethanol administration induces short-and long-term changes in enkephalin and dynorphin tissue concentrations in rat brain. Alcohol 22 (2000) 165-171
135. Locke K.W., Brown D.R., and Holtzman S.G. Effects of opiate antagonists and putative mu-and kappa-agonists on milk intake in rat and squirrel monkey. Pharmacol. Biochem. Behav. 17 (1982) 1275-1279
136. Lord J.A., Waterfield A.A., Hughes J., and Kosterlitz H.W. Endogenous opioid peptides: multiple agonists and receptors. Nature 267 (1977) 495-499
137. Lu Z. Mechanism of rectification in inward-rectifier K+channels. Annu. Rev. Physiol. 66 (2004) 103-129
138. Lyketsos C.G., and Olin J. Depression in Alzheimer's disease: overview and treatment. Biol. Psychiatry 52 (2002) 243-252
139. Macdonald R.L., and Werz M.A. Dynorphin A decreases voltage-dependent calcium conductance of mouse dorsal root ganglion neurones. J. Physiol. 377 (1986) 237-249
140. Macey D.J., Koob G.F., and Markou A. CRF and urocortin decreased brain stimulation reward in the rat: reversal by a CRF receptor antagonist. Brain Res. 866 (2000) 82-91
141. Mague S.D., Pliakas A.M., Todtenkopf M.S., Tomasiewicz H.C., Zhang Y., Stevens Jr. W.C., Jones R.M., Portoghese P.S., and Carlezon Jr. W.A. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J. Pharmacol. Exp. Ther. 305 (2003) 323-330
142. Maisonneuve I.M., Archer S., and Glick S.D. U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci. Lett. 181 (1994) 57-60
143. Malmnas C.O. The significance of dopamine, versus other catecholamines, for l-dopa induced facilitation of sexual behavior in the castrated male rat. Pharmacol. Biochem. Behav. 4 (1976) 521-526
144. Mansour A., Burke S., Pavlic R.J., Akil H., and Watson S.J. Immunohistochemical localization of the cloned kappa 1 receptor in the rat CNS and pituitary. Neuroscience 71 (1996) 671-690
145. Mansour A., Fox C.A., Akil H., and Watson S.J. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 18 (1995) 22-29
146. Mansour A., Khachaturian H., Lewis M.E., Akil H., and Watson S.J. Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J. Neurosci. 7 (1987) 2445-2464
147. Margolis E.B., Lock H., Chefer V.I., Shippenberg T.S., Hjelmstad G.O., and Fields H.L. Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 2938-2942
148. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., and Gilbert P.E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197 (1976) 517-532
149. Marzuk P.M., Tardiff K., Leon A.C., Stajic M., Morgan E.B., and Mann J.J. Prevalence of cocaine use among residents of New York City who committed suicide during a one-year period. Am. J. Psychiatry. 149 (1992) 371-375
150. Maslowski R.J., and Napier T.C. Dopamine D1 and D2 receptor agonists induce opposite changes in the firing rate of ventral pallidal neurons. Eur. J. Pharmacol. 200 (1991) 103-112
151. McLaughlin J.P., Li S., Valdez J., Chavkin T.A., and Chavkin C. Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system. Neuropsychopharmacology 31 (2006) 1241-1248
152. Melendez R.I., Rodd-Henricks Z.A., McBride W.J., and Murphy J.M. Alcohol stimulates the release of dopamine in the ventral pallidum but not in the globus pallidus: a dual-probe microdialysis study. Neuropsychopharmacology 28 (2003) 939-946
153. Meng F., Xie G.X., Thompson R.C., Mansour A., Goldstein A., Watson S.J., and Akil H. Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 9954-9958
154. Meshul C.K., and McGinty J.F. Kappa opioid receptor immunoreactivity in the nucleus accumbens and caudate-putamen is primarily associated with synaptic vesicles in axons. Neuroscience 96 (2000) 91-99
155. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J.L., Guillemot J.C., Ferrara P., and Monsarrat B. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377 (1995) 532-535
156. Minamino N., Kangawa K., Chino N., Sakakibara S., and Matsuo H. Beta-neo-endorphin, a new hypothalamic "big" Leu-enkephalin of porcine origin: its purification and the complete amino acid sequence. Biochem. Biophys. Res. Commun. 99 (1981) 864-870
157. Minamino N., Kangawa K., Fukuda A., Matsuo H., and Iagarashi M. A new opioid octapeptide related to dynorphin from porcine hypothalamus. Biochem. Biophys. Res. Commun. 95 (1980) 1475-1481
158. Mogil J.S., and Pasternak G.W. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol. Rev. 53 (2001) 381-415
159. Mollereau C., Parmentier M., Mailleux P., Butour J.L., Moisand C., Chalon P., Caput D., Vassart G., and Meunier J.C. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett. 341 (1994) 33-38
160. Morley J.E., Elson M.K., Levine A.S., and Shafer R.B. The effects of stress on central nervous system concentrations of the opioid peptide, dynorphin. Peptides 3 (1982) 901-906
161. Morley J.E., and Levine A.S. Stress-induced eating is mediated through endogenous opiates. Science 209 (1980) 1259-1261
162. Morley J.E., and Levine A.S. Dynorphin-(1-13) induces spontaneous feeding in rats. Life Sci. 29 (1981) 1901-1903
163. Morley J.E., and Levine A.S. Corticotrophin releasing factor, grooming and ingestive behavior. Life Sci. 31 (1982) 1459-1464
164. Mucha R.F., and Herz A. Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology (Berl.) 86 (1985) 274-280
165. Nakanishi S., Inoue A., Kita T., Nakamura M., Chang A.C., Cohen S.N., and Numa S. Nucleotide sequence of cloned cDNA for bovine corticotropin-beta-lipotropin precursor. Nature 278 (1979) 423-427
166. Negus S.S., Mello N.K., Portoghese P.S., and Lin C.E. Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J. Pharmacol. Exp. Ther. 282 (1997) 44-55
167. Nencini P., and Stewart J. Chronic systemic administration of amphetamine increases food intake to morphine, but not to U50-488H, microinjected into the ventral tegmental area in rats. Brain Res. 527 (1990) 254-258
168. Newton S.S., Thome J., Wallace T.L., Shirayama Y., Schlesinger L., Sakai N., Chen J., Neve R., Nestler E.J., and Duman R.S. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J. Neurosci. 22 (2002) 10883-10890
169. Nicola S.M., Surmeier J., and Malenka R.C. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu. Rev. Neurosci. 23 (2000) 185-215
170. Nishi A., Bibb J.A., Snyder G.L., Higashi H., Nairn A.C., and Greengard P. Amplification of dopaminergic signaling by a positive feedback loop. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 12840-12845
171. Noback C.R., Demarest R.J., and Ruggiero D.A. The Human Nervous System: Structure and Function (2005), Humana Press, Totowa, NJ
172. Noda M., Furutani Y., Takahashi H., Toyosato M., Hirose T., Inayama S., Nakanishi S., and Numa S. Cloning and sequence analysis of cDNA for bovine adrenal preproenkephalin. Nature 295 (1982) 202-206
173. O'Dell L.E., Roberts A.J., Smith R.T., and Koob G.F. Enhanced alcohol self-administration after intermittent versus continuous alcohol vapor exposure. Alcohol. Clin. Exp. Res. 28 (2004) 1676-1682
174. Olianas M.C., Concas D., and Onali P. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors. Br. J. Pharmacol. 147 (2006) 360-370
175. Parsons L.H., Smith A.D., and Justice Jr. J.B. Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine. Synapse 9 (1991) 60-65
176. Paulson P.E., and Robinson T.E. Amphetamine-induced time-dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum: a microdialysis study in behaving rats. Synapse 19 (1995) 56-65
177. Paulson P.E., and Robinson T.E. Regional differences in the effects of amphetamine withdrawal on dopamine dynamics in the striatum. Analysis of circadian patterns using automated on-line microdialysis. Neuropsychopharmacology 14 (1996) 325-337
178. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1998), Academic Press, San Diego
179. Pennartz C.M., Groenewegen H.J., and Lopes da Silva F.H. The nucleus accumbens as a complex of functionally distinct neuronal ensembles: an integration of behavioural, electrophysiological and anatomical data. Prog. Neurobiol. 42 (1994) 719-761
180. Pfaus J.G., Damsma G., Nomikos G.G., Wenkstern D.G., Blaha C.D., Phillips A.G., and Fibiger H.C. Sexual behavior enhances central dopamine transmission in the male rat. Brain Res. 530 (1990) 345-348
181. Pfeiffer A., Brantl V., Herz A., and Emrich H.M. Psychotomimesis mediated by kappa opiate receptors. Science 233 (1986) 774-776
182. Phillips A.G., and Lepiane F.G. Reward produced by microinjection of (D-Ala2),Met5-enkephalinamide into the ventral tegmental area. Behav. Brain Res. 5 (1982) 225-229
183. Pliakas A.M., Carlson R.R., Neve R.L., Konradi C., Nestler E.J., and Carlezon Jr. W.A. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. J. Neurosci. 21 (2001) 7397-7403
184. Plotsky P.M., Thrivikraman K.V., Nemeroff C.B., Caldji C., Sharma S., and Meaney M.J. Long-term consequences of neonatal rearing on central corticotropin-releasing factor systems in adult male rat offspring. Neuropsychopharmacology 30 (2005) 2192-2204
185. Prather P.L., McGinn T.M., Claude P.A., Liu-Chen L.Y., Loh H.H., and Law P.Y. Properties of a kappa-opioid receptor expressed in CHO cells: interaction with multiple G-proteins is not specific for any individual G alpha subunit and is similar to that of other opioid receptors. Brain Res. Mol. Brain Res. 29 (1995) 336-346
186. Przewlocka B., Turchan J., Lason W., and Przewlocki R. Ethanol withdrawal enhances the prodynorphin system activity in the rat nucleus accumbens. Neurosci. Lett. 238 (1997) 13-16
187. Pucilowski O. Psychopharmacological properties of calcium channel inhibitors. Psychopharmacology (Berl.) 109 (1992) 12-29
188. Quirion R., Hammer Jr. R.P., Herkenham M., and Pert C.B. Phencyclidine (angel dust)/sigma "opiate" receptor: visualization by tritium-sensitive film. Proc. Natl. Acad. Sci. U. S. A. 78 (1981) 5881-5885
189. Rada P., Moreno S.A., Tucci S., Gonzalez L.E., Harrison T., Chau D.T., Hoebel B.G., and Hernandez L. Glutamate release in the nucleus accumbens is involved in behavioral depression during the PORSOLT swim test. Neuroscience 119 (2003) 557-565
190. Rawls S.M., and McGinty J.F. Kappa receptor activation attenuates l-trans-pyrrolidine-2,4-dicarboxylic acid-evoked glutamate levels in the striatum. J. Neurochem. 70 (1998) 626-634
191. Reijnders J.S., Ehrt U., Weber W.E., Aarsland D., and Leentjens A.F. A systematic review of prevalence studies of depression in Parkinson's disease. Mov. Disord. 23 (2008) 183-189
192. Rimoy G.H., Wright D.M., Bhaskar N.K., and Rubin P.C. The cardiovascular and central nervous system effects in the human of U-62066E. A selective opioid receptor agonist. Eur. J. Clin. Pharmacol. 46 (1994) 203-207
193. Robbins T.W., Cador M., Taylor J.R., and Everitt B.J. Limbic-striatal interactions in reward-related processes. Neurosci. Biobehav. Rev. 13 (1989) 155-162
194. Robbins T.W., and Everitt B.J. Functional studies of the central catecholamines. Int. Rev. Neurobiol. 23 (1982) 303-365
195. Rossetti Z.L., Longu G., Mercuro G., and Gessa G.L. Extraneuronal noradrenaline in the prefrontal cortex of morphine-dependent rats: tolerance and withdrawal mechanisms. Brain Res. 609 (1993) 316-320
196. Ruegg H., Yu W.Z., and Bodnar R.J. Opioid-receptor subtype agonist-induced enhancements of sucrose intake are dependent upon sucrose concentration. Physiol. Behav. 62 (1997) 121-128
197. Rylkova D., Boissoneault J., Isaac S., Prado M., Shah H.P., and Bruijnzeel A.W. Effects of NPY and the specific Y1 receptor agonist [D-His(26)]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats. Neuropeptides 42 (2008) 215-227
198. Salzet M., and Tasiemski A. Involvement of pro-enkephalin-derived peptides in immunity. Dev. Comp. Immunol. 25 (2001) 177-185
199. Schenk S., Partridge B., and Shippenberg T.S. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology (Berl.) 144 (1999) 339-346
200. Schlussman S.D., Zhou Y., Bailey A., Ho A., and Kreek M.J. Steady-dose and escalating-dose "binge" administration of cocaine alter expression of behavioral stereotypy and striatal preprodynorphin mRNA levels in rats. Brain Res. Bull. 67 (2005) 169-175
201. Schulteis G., Markou A., Gold L.H., Stinus L., and Koob G.F. Relative sensitivity to naloxone of multiple indices of opiate withdrawal: a quantitative dose-response analysis. J. Pharmacol. Exp. Ther. 271 (1994) 1391-1398
202. Seligman M.E., and Beagley G. Learned helplessness in the rat. J. Comp. Physiol. Psychol. 88 (1975) 534-541
203. Shaham Y., Erb S., and Stewart J. Stress-induced relapse to heroin and cocaine seeking in rats: a review. Brain Res. Brain Res. Rev. 33 (2000) 13-33
204. Shippenberg T.S., and Herz A. Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu- and kappa-opioid agonists. Brain Res. 436 (1987) 169-172
205. Shirayama Y., Ishida H., Iwata M., Hazama G.I., Kawahara R., and Duman R.S. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J. Neurochem. 90 (2004) 1258-1268
206. Simonin F., Gaveriaux-Ruff C., Befort K., Matthes H., Lannes B., Micheletti G., Mattei M.G., Charron G., Bloch B., and Kieffer B. kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7006-7010
207. Simonin F., Valverde O., Smadja C., Slowe S., Kitchen I., Dierich A., Le M.M., Roques B.P., Maldonado R., and Kieffer B.L. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J. 17 (1998) 886-897
208. Singh N.A., Midgley L.P., Bush L.G., Gibb J.W., and Hanson G.R. N-methyl-d-aspartate receptors mediate dopamine-induced changes in extrapyramidal and limbic dynorphin systems. Brain Res. 555 (1991) 233-238
209. Sinha R. How does stress increase risk of drug abuse and relapse?. Psychopharmacology (Berl.) 158 (2001) 343-359
210. Sivam S.P. Cocaine selectively increases striatonigral dynorphin levels by a dopaminergic mechanism. J. Pharmacol. Exp. Ther. 250 (1989) 818-824
211. Sizemore G.M., Co C., and Smith J.E. Ventral pallidal extracellular fluid levels of dopamine, serotonin, gamma amino butyric acid, and glutamate during cocaine self-administration in rats. Psychopharmacology (Berl.) 150 (2000) 391-398
212. Smagin G.N., Howell L.A., Redmann Jr. S., Ryan D.H., and Harris R.B. Prevention of stress-induced weight loss by third ventricle CRF receptor antagonist. Am. J. Physiol. 276 (1999) R1461-R1468
213. Smiley P.L., Johnson M., Bush L., Gibb J.W., and Hanson G.R. Effects of cocaine on extrapyramidal and limbic dynorphin systems. J. Pharmacol. Exp. Ther. 253 (1990) 938-943
214. Smith B.R., Brown Z.W., and Amit Z. Intraventricular self-administration of leucine-enkephalin by laboratory rats. Life Sci. 31 (1982) 1527-1530
215. Smith K.S., Tindell A.J., Aldridge J.W., and Berridge K.C. Ventral pallidum roles in reward and motivation. Behav. Brain Res. 196 (2009) 155-167
216. Spanagel R., Almeida O.F., Bartl C., and Shippenberg T.S. Endogenous kappa-opioid systems in opiate withdrawal: role in aversion and accompanying changes in mesolimbic dopamine release. Psychopharmacology (Berl.) 115 (1994) 121-127
217. Spanagel R., Herz A., and Shippenberg T.S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 2046-2050
218. Spyraki C., Fibiger H.C., and Phillips A.G. Attenuation by haloperidol of place preference conditioning using food reinforcement. Psychopharmacology (Berl.) 77 (1982) 379-382
219. Spyraki C., Fibiger H.C., and Phillips A.G. Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system. Psychopharmacology (Berl.) 79 (1983) 278-283
220. Spyraki C., Nomikos G.G., and Varonos D.D. Intravenous cocaine-induced place preference: attenuation by haloperidol. Behav. Brain Res. 26 (1987) 57-62
221. Stahl S.M., and Wise D.D. The potential role of a corticotropin-releasing factor receptor-1 antagonist in psychiatric disorders. CNS Spectr. 13 (2008) 467-483
222. Sukhov R.R., Walker L.C., Rance N.E., Price D.L., and Young III W.S. Opioid precursor gene expression in the human hypothalamus. J. Comp. Neurol. 353 (1995) 604-622
223. Suzuki T., Funada M., Narita M., Misawa M., and Nagase H. Morphine-induced place preference in the CXBK mouse: characteristics of mu opioid receptor subtypes. Brain Res. 602 (1993) 45-52
224. Suzuki T., Shiozaki Y., Masukawa Y., Misawa M., and Nagase H. The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference. Jpn. J. Pharmacol. 58 (1992) 435-442
225. Svenningsson P., Lindskog M., Ledent C., Parmentier M., Greengard P., Fredholm B.B., and Fisone G. Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 1856-1860
226. Swanson L.W. The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res. Bull. 9 (1982) 321-353
227. Tallent M., Dichter M.A., Bell G.I., and Reisine T. The cloned kappa opioid receptor couples to an N-type calcium current in undifferentiated PC-12 cells. Neuroscience 63 (1994) 1033-1040
228. Telner J.I., and Singhal R.L. Effects of nortriptyline treatment on learned helplessness in the rat. Pharmacol. Biochem. Behav. 14 (1981) 823-826
229. Todtenkopf M.S., Marcus J.F., Portoghese P.S., and Carlezon Jr. W.A. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology (Berl.) 172 (2004) 463-470
230. Tomasiewicz H.C., Todtenkopf M.S., Chartoff E.H., Cohen B.M., and Carlezon Jr. W.A. The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward. Biol. Psychiatry 64 (2008) 982-988
231. Traynor J. Subtypes of the kappa-opioid receptor: fact or fiction?. Trends Pharmacol. Sci. 10 (1989) 52-53
232. Trujillo K.A., and Akil H. Pharmacological regulation of striatal prodynorphin peptides. Prog. Clin. Biol. Res. 328 (1990) 223-226
233. Tsai G., and Coyle J.T. The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu. Rev. Med. 49 (1998) 173-184
234. Tsai G., Gastfriend D.R., and Coyle J.T. The glutamatergic basis of human alcoholism. Am. J. Psychiatry 152 (1995) 332-340
235. Tseng L.F., Loh H.H., and Li C.H. Beta-endorphin as a potent analgesic by intravenous injection. Nature 263 (1976) 239-240
236. Tsuji M., Takeda H., Matsumiya T., Nagase H., Narita M., and Suzuki T. The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice. Life Sci. 68 (2001) 1717-1725
237. Tulunay F.C., Jen M.F., Chang J.K., Loh H.H., and Lee N.M. Possible regulatory role of dynorphin on morphine-and beta-endorphin-induced analgesia. J. Pharmacol. Exp. Ther. 219 (1981) 296-298
238. van Ree J.M., Smyth D.G., and Colpaert F.C. Dependence creating properties of lipotropin C-fragment (beta-endorphin): evidence for its internal control of behavior. Life Sci. 24 (1979) 495-502
239. Walker B.M., and Koob G.F. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 33 (2008) 643-652
240. Walker B.M., and Koob G.F. Regarding "Dynorphin is a downstream effector of striatal BDNF regulation of ethanol intake". FASEB J. 22 (2008) 2113-2114
241. Walker J.M., Thompson L.A., Frascella J., and Friederich M.W. Opposite effects of mu and kappa opiates on the firing-rate of dopamine cells in the substantia nigra of the rat. Eur. J. Pharmacol. 134 (1987) 53-59
242. Walsh S.L., Strain E.C., Abreu M.E., and Bigelow G.E. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl.) 157 (2001) 151-162
243. Weber E., and Barchas J.D. Immunohistochemical distribution of dynorphin B in rat brain: relation to dynorphin A and alpha-neo-endorphin systems. Proc. Natl. Acad. Sci. U. S. A. 80 (1983) 1125-1129
244. Weber E., Roth K.A., and Barchas J.D. Colocalization of alpha-neo-endorphin and dynorphin immunoreactivity in hypothalamic neurons. Biochem. Biophys. Res. Commun. 103 (1981) 951-958
245. Weber E., Roth K.A., and Barchas J.D. Immunohistochemical distribution of alpha-neo-endorphin/dynorphin neuronal systems in rat brain: evidence for colocalization. Proc. Natl. Acad. Sci. U. S. A. 79 (1982) 3062-3066
246. Weiss F., Markou A., Lorang M.T., and Koob G.F. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res. 593 (1992) 314-318
247. Weiss F., Parsons L.H., Schulteis G., Hyytia P., Lorang M.T., Bloom F.E., and Koob G.F. Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats. J. Neurosci. 16 (1996) 3474-3485
248. Weissman B.A., and Zamir N. Differential effects of heroin on opioid levels in the rat brain. Eur. J. Pharmacol. 139 (1987) 121-123
249. Wen H.L., and Ho W.K. Suppression of withdrawal symptoms by dynorphin in heroin addicts. Eur. J. Pharmacol. 82 (1982) 183-186
250. Wen H.L., Ho W.K., and Wen P.Y. Comparison of the effectiveness of different opioid peptides in suppressing heroin withdrawal. Eur. J. Pharmacol. 100 (1984) 155-162
251. Werling L.L., McMahon P.N., and Cox B.M. Selective tolerance at mu and kappa opioid receptors modulating norepinephrine release in guinea pig cortex. J. Pharmacol. Exp. Ther. 247 (1988) 1103-1106
252. Werz M.A., and Macdonald R.L. Dynorphin reduces calcium-dependent action potential duration by decreasing voltage-dependent calcium conductance. Neurosci. Lett. 46 (1984) 185-190
253. Wise R.A. Dopamine, learning and motivation. Nat. Rev. Neurosci. 5 (2004) 483-494
254. Wise R.A., Spindler J., deWit H., and Gerberg G.J. Neuroleptic-induced "anhedonia" in rats: pimozide blocks reward quality of food. Science 201 (1978) 262-264
255. Xi Z.X., Ramamoorthy S., Shen H., Lake R., Samuvel D.J., and Kalivas P.W. GABA transmission in the nucleus accumbens is altered after withdrawal from repeated cocaine. J. Neurosci. 23 (2003) 3498-3505
256. Xie G.X., Meng F., Mansour A., Thompson R.C., Hoversten M.T., Goldstein A., Watson S.J., and Akil H. Primary structure and functional expression of a guinea pig kappa opioid (dynorphin) receptor. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 3779-3783
257. Yasuda K., Raynor K., Kong H., Breder C.D., Takeda J., Reisine T., and Bell G.I. Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 6736-6740
258. Yoshida M., Yokoo H., Tanaka T., Mizoguchi K., Emoto H., Ishii H., and Tanaka M. Facilitatory modulation of mesolimbic dopamine neuronal activity by a mu-opioid agonist and nicotine as examined with in vivo microdialysis. Brain Res. 624 (1993) 277-280
259. You Z.B., Herrera-Marschitz M., and Terenius L. Modulation of neurotransmitter release in the basal ganglia of the rat brain by dynorphin peptides. J. Pharmacol. Exp. Ther. 290 (1999) 1307-1315
260. Zamir N., Palkovits M., and Brownstein M.J. Distribution of immunoreactive beta-neo-endorphin in discrete areas of the rat brain and pituitary gland: comparison with alpha-neo-endorphin. J. Neurosci. 4 (1984) 1248-1252
261. Zamir N., Palkovits M., and Brownstein M.J. The distribution of immunoreactive alpha-neo-endorphin in the central nervous system of the rat. J. Neurosci. 4 (1984) 1240-1247
262. Zhang Y., Butelman E.R., Schlussman S.D., Ho A., and Kreek M.J. Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology (Berl.) 173 (2004) 146-152
263. Zhang Y., Butelman E.R., Schlussman S.D., Ho A., and Kreek M.J. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl.) 179 (2005) 551-558
264. Zhou Y., Cui C.L., Schlussman S.D., Choi J.C., Ho A., Han J.S., and Kreek M.J. Effects of cocaine place conditioning, chronic escalating-dose "binge" pattern cocaine administration and acute withdrawal on orexin/hypocretin and preprodynorphin gene expressions in lateral hypothalamus of Fischer and Sprague-Dawley rats. Neuroscience 153 (2008) 1225-1234
265. Zhu J., Chen C., Xue J.C., Kunapuli S., DeRiel J.K., and Liu-Chen L.Y. Cloning of a human kappa opioid receptor from the brain. Life Sci. 56 (1995) 201-207
266. Zukin R.S., Eghbali M., Olive D., Unterwald E.M., and Tempel A. Characterization and visualization of rat and guinea pig brain kappa opioid receptors: evidence for kappa 1 and kappa 2 opioid receptors. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 4061-4065